ITOS
Companies
NASDAQ
Iteos Therapeutics Inc.
Health Care
$9.97
+$2.29 (+29.82%)
Price Chart
Overview
About ITOS
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Market Cap
$603.3M
Volume
27.2M
Avg. Volume
12.8M
P/E Ratio
-1.4273505
Dividend Yield
0.00%
Employees
140.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.71
Low Correlation
Volatility
High (0.60)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ITOS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$603.3M
Volume27.2M
P/E Ratio-1.43
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
April 29, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025